Home / News / India News / Article /
Bharat Biotech claims Covaxin 81 per cent efficient in Phase 3 trials
Updated On: 03 March, 2021 12:00 AM IST | New Delhi | PTI
However, it is not clear if the drugmaker has published the results of the vaccine’s Phase III clinical trials to back up its claim
Listen to this article :

Photo for representational purpose
Bharat Biotech on Wednesday said its COVID-19 vaccine Covaxin has demonstrated an interim vaccine efficacy of 81 per cent in Phase 3 clinical trials.
The process involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research, the Hyderabad-based firm said in a statement.
Read Next Story


